Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19367982 | 0.86 | LMNA (0.57) | L3MBTL1SMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL4564262 | 0.81 | L3MBTL1 (0.59) | L3MBTL1SMN1; SMN2LMNAPOLBNAAA | |
| SCHEMBL12630763 | 0.80 | OPRK1 (0.47) | HPGDSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL5709109 | 0.80 | L3MBTL1 (0.60) | L3MBTL1SMN1; SMN2LMNAPOLBPRSS1 | |
| SCHEMBL668703 | 0.78 | L3MBTL1 (0.59) | L3MBTL1SMN1; SMN2LMNAPOLBPRSS1 | |
| SCHEMBL364448 | 0.78 | HPGD (0.87) | HPGDSMN1; SMN2LMNAPOLBPRSS1 | |
| SCHEMBL3192014 | 0.76 | LMNA (0.77) | HPGDSMN1; SMN2LMNAPOLBPRSS1 | |
| SCHEMBL15625518 | 0.76 | L3MBTL1 (0.61) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL28011647 | 0.75 | NAAA (0.52) | HPGDL3MBTL1SMN1; SMN2LMNAPOLB | |
| SCHEMBL4039186 | 0.75 | ALDH1A1 (0.83) | HPGDSMN1; SMN2LMNAPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110329-B2 | Charge controlling agent and toner | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CANON KABUSHIKI KAISHA (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CANON KABUSHIKI KAISHA (JP) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111125-A1 | CHARGE CONTROLLING AGENT AND TONER | CA2, ACTR2, CA12 | HPGD 4319/4885L3MBTL1 4774/4885SMN1; SMN2 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.